Leading the Way in Life Science Technologies

GEN Exclusives

More »

Market and Technology Analysis

More »
Oct 10, 2013

Long Noncoding RNAs: Why You Need to Know about Them Now

lncRNA space could be twice as big as the miRNA space as they seem to have tremendous potential as disease biomarkers.

Long Noncoding RNAs: Why You Need to Know about Them Now

Research in this report shows the potential for the lncRNA research marketplace to expand in the future—we are just at the beginning stages of market development at this point. [Figure Source: LLNL.gov]

  • The focus of this GEN Market & Tech Analysis Report is to present some of our recent industry tracking of the long noncoding RNAs (lncRNAs) space as a follow-on to the GEN Report on microRNA Associations and Signatures.

    In this report, we present the following: 

    • Frame the position of lncRNAs vis-à-vis other classes of RNAs
    • Current breakout of the research marketplace as to which segments of research activity on lncRNAs are being focused upon
    • Publication analysis of the key lncRNAs across different disease classes

    A key driver for the interest in lncRNAs is their sheer number in the genome (tens of thousands of lncRNAs are believed to exist) and the multitude of roles they are believed to play including structural roles, modulation/fine-tuning of gene expression in vivo, and epigenetic effects. Indeed, some lncRNAs have been associated with cancer and a few reports even suggest the possibility of lncRNAs with biomarker potential.

    CLICK HERE to download the PDF report.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »